Javascript must be enabled to continue!
Formulation and evaluation of topical piroxicam microemulgel for arthritis
View through CrossRef
Background: Piroxicam is an anti-inflammatory, analgesic, and antipyretic drug. Piroxicam is widely used in the management of chronic pain. The objective of this work was to develop and analyze topical Piroxicam microemulgel to improve drug solubility, enhance permeation, reduce GIT side effects reduce the frequency of the drug. Method: The Piroxicam microemulgel was prepared by drawing the pseudo ternary phase picture and water titration procedure. Formulation was prepared by using isopropyl myristate as an oil, Tween 80 as an surfactant, n-butanol as Co-surfactant and water. It was converted to gel by using 1% Carbopol 940 and few drops of ethanolamine. The prepared formulation was characterized for thermodynamic stability, pH, droplet size, viscosity, FTIR,DSC, electrical conductivity, dye solubility drug content, and in-vitro release using a Franz diffusion cell. Result: Microemulgel formulation was thermodynamically stable on visual inspection after being treated with a freeze-thaw cycle and centrifugation. pH of formulation was 6.5. The mean droplet size for ME gel was 100±0.472nm. The viscosity of the microemulgel was 90.4±0.01 cps which showed Newtonian flow. FTIR and DSC studies showed that microemulgel was compatible with its excipients. Electrical conductivity and dye solubility testing confirmed that the microemulgel was O/W. Piroxicam microemulsion gel showed 89.89% drug content and the release rate of piroxicam was 98±8.63% after 48h. It followed the Korsmeyer Pappas model which means it was a hydrogel-based system. Conclusion: Microemulsion gel formulation obtained remarkably inflated skin retention for piroxicam over the piroxicam gel. It might act as a promising vehicle for the topical delivery of poor water-soluble drugs.
AMMANIF Academic Publisher
Title: Formulation and evaluation of topical piroxicam microemulgel for arthritis
Description:
Background: Piroxicam is an anti-inflammatory, analgesic, and antipyretic drug.
Piroxicam is widely used in the management of chronic pain.
The objective of this work was to develop and analyze topical Piroxicam microemulgel to improve drug solubility, enhance permeation, reduce GIT side effects reduce the frequency of the drug.
Method: The Piroxicam microemulgel was prepared by drawing the pseudo ternary phase picture and water titration procedure.
Formulation was prepared by using isopropyl myristate as an oil, Tween 80 as an surfactant, n-butanol as Co-surfactant and water.
It was converted to gel by using 1% Carbopol 940 and few drops of ethanolamine.
The prepared formulation was characterized for thermodynamic stability, pH, droplet size, viscosity, FTIR,DSC, electrical conductivity, dye solubility drug content, and in-vitro release using a Franz diffusion cell.
Result: Microemulgel formulation was thermodynamically stable on visual inspection after being treated with a freeze-thaw cycle and centrifugation.
pH of formulation was 6.
5.
The mean droplet size for ME gel was 100±0.
472nm.
The viscosity of the microemulgel was 90.
4±0.
01 cps which showed Newtonian flow.
FTIR and DSC studies showed that microemulgel was compatible with its excipients.
Electrical conductivity and dye solubility testing confirmed that the microemulgel was O/W.
Piroxicam microemulsion gel showed 89.
89% drug content and the release rate of piroxicam was 98±8.
63% after 48h.
It followed the Korsmeyer Pappas model which means it was a hydrogel-based system.
Conclusion: Microemulsion gel formulation obtained remarkably inflated skin retention for piroxicam over the piroxicam gel.
It might act as a promising vehicle for the topical delivery of poor water-soluble drugs.
Related Results
Formulation and characterization of piroxicam/cyclodextrin taste masked oral lyophilisates
Formulation and characterization of piroxicam/cyclodextrin taste masked oral lyophilisates
Oral lyophilisates are one of the orodispersible tablets produced by lyophilization technique. Due to their porous structure, they instantly disintegrate when contacting saliva. Ge...
Phytoconstituent Based Microemulgel: A Novel Topical Drug Delivery Approach
Phytoconstituent Based Microemulgel: A Novel Topical Drug Delivery Approach
A huge amount of Indian medicinal plants are accredited with various pharmacological activities. Extract of medicinal plant and extracted oil have more or less pharmacological prop...
Formulation, development and characterization of ibuprofen microemulgel for arthritis
Formulation, development and characterization of ibuprofen microemulgel for arthritis
Objective: Microemulgel is composed of aqueous phase, lipophilic phase, along with surfactant and co-surfactant, a suitable gelling agent is also incorporated. The drug Ibuprofen i...
Piroxicam‐induced fixed drug eruption: Cross‐reactivity with meloxicam
Piroxicam‐induced fixed drug eruption: Cross‐reactivity with meloxicam
BackgroundNon‐steroidal anti‐inflammatory drugs constitute a main cause of fixed drug eruption (FDE). A few cases of piroxicam‐induced FDE have been reported; however, the cross‐re...
Formulation, Characterization of Piroxicam Ointment for Topical Drug Delivery with various Enhancers
Formulation, Characterization of Piroxicam Ointment for Topical Drug Delivery with various Enhancers
The primary objective of the current study was to develop and then assess Piroxicam ointment with penetration enhancers, including castor oil, thymus oil, and clove oil. As per B...
Risk factors and comorbidities for psoriatic arthritis. Literature review
Risk factors and comorbidities for psoriatic arthritis. Literature review
Introduction:
Psoriatic arthritis is a chronic disease involving peripheral arthritis, spondylitis, dactylitis (inflammation of the whole digit) and enthesitis. It is a disease e...
DIAGNOSIS DAN TATALAKSANA KOMPREHENSIF OSTEOARTRITIS
DIAGNOSIS DAN TATALAKSANA KOMPREHENSIF OSTEOARTRITIS
Rheumatic conditions are composed of arthritis and its allied connective tissue diseases. There arecurrently more than 100 discrete forms of arthritis recognized, the most common b...
THE AUSTRALIAN RHEUMATOLOGY ASSOCIATION
THE AUSTRALIAN RHEUMATOLOGY ASSOCIATION
The followina are abstracts of papers presented at the 35th Annual Scientific Meeting of the Australian Rheumatology Association, held in Perth, Western Australia, 1–4 December. 19...

